As recent studies indicate, despite the established association between PIK3CA mutations, diminished PTEN expression, and the variability of dual-inhibitor effects in RA-FLSs, reproducible biomarker panels enabling individualized prediction of therapeutic response remain conspicuously absent [81,89]. This evidence concerns the gene PTEN and rheumatoid arthritis.